Company Financials: Orthopaedics and Spine

• Posted in Business Critical | October 04, 2012 | Comments (0)
• Tags: earnings, financial, company financials, sales
• By: Julie A. Vetalice

ORTHOWORLD’s estimates place overall 2Q12 market growth at 5% over 2Q11, as shown in Exhibit 1. Performance highlights follow and pertain to 2Q12, unless noted otherwise.

Exhibit 1: Increases by Product Segment: 2Q12 vs. 2Q11

 

NOTES TO EXHIBIT 1

1 Orthopaedic products; constant currency, pro forma growth
2 Includes biologics
3 For the quarter ended 5/31/12; includes Dental. Spine includes Bone Stim and Biologics; Bone Stim reflects all Bone Healing sales.
4 For the quarter ended 7/27/12
5 Spine
6 For the quarter ended 6/30/12
7 Extremities: extremities + fixation combined; Endoscopy: endoscopic + communications, most of which is orthopaedic; Spine: neuro + spine. Total growth excludes Patient Handling.
8 ORTHOWORLD estimates